Obinutuzumab (GA101) - A different anti-CD20 antibody with great expectations

Expert Opinion on Biological Therapy

Volumn 12, Issue 5, 2012, Pages 543-545

  Illidge, Tim M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

CD20; immunotherapy; lymphoid malignancies; mAb; newer agents

Indexed keywords

B 020999; CD20 ANTIBODY; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; FC RECEPTOR; MONOCLONAL ANTIBODY; OBINUTUZUMAB; REACTIVE OXYGEN METABOLITE; RITUXIMAB; TOSITUMOMAB; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; EFFECTOR CELL; FOLLICULAR LYMPHOMA; HUMAN; LIPID RAFT; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; LYSOSOME; MONOTHERAPY; NONHUMAN; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD20; HUMANS;

EID: 84859619461     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.668881     Document Type: Editorial

References (15)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-Cell lymphoma. N Engl J Med 2002;346(4):235-42 (Pubitemid 34438862)
2. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99(9):706-14 (Pubitemid 47078732)
3. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74
4. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115(22):4393-402
5. Cragg MS, Morgan SM, Chan HTC, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101(3):1045-52 (Pubitemid 36139378)
6. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44(16):3823-37 (Pubitemid 47332625)
7. Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009;119(8):2143-59
8. Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011;117(17):4519-29
9. Honeychurch J, Alduaij W, Azizyan M, et al. Antibody-induced non-apoptotic cell death is mediated through the generation of reactive oxygen species by NADPH oxidase in human lymphoma and leukemia cells. Blood 2012;In press
10. Alduaij W, Illidge TM. The future of anti-CD20 monoclonal antibodies: are we making progress? Blood 2011;117(11):2993-3001
11. Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009;113(20):4885-93
12. Beum PV, Kennedy AD, Williams ME, et al. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006;176(4):2600-9 (Pubitemid 43201712)
13. Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115(25):5191-201
14. Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing GA101 (Obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-Cell Non-Hodgkin lymphoma: preliminary analysis of the GAUSS Study. ASH Annu Meeting Abstr 2011;118:269
15. Salles GA, Morschhauser F, Thieblemont C, et al. Efficacy and safety of obinutuzumab (GA101) monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma: results from a phase I/II study (BO20999). Blood 2011;624a